NCT04418466View on ClinicalTrials.gov

Safety, Tolerability, and Pharmacokinetics of Switching From Oral Risperidone to Risperidone Implant

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

April 1, 2021

Primary Completion Date

February 10, 2023

Study Completion Date

February 10, 2023

Conditions
Schizophrenia
Interventions
COMBINATION_PRODUCT

Risperidone

Risperidone Implant

Trial Locations (2)

33016

Segal Trials, Miami Lakes

90806

Collaborative Neuroscience Research, Long Beach

All Listed Sponsors
collaborator

National Institute of Mental Health (NIMH)

NIH

lead

Delpor, Inc.

INDUSTRY

NCT04418466 - Safety, Tolerability, and Pharmacokinetics of Switching From Oral Risperidone to Risperidone Implant | Biotech Hunter | Biotech Hunter